VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

    NEXT STORY
    Exagen Inc. Announces $26.2 Million Debt Refinancing
    PREV STORY
    Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Molecular Diagnostics for Infectious Disease – Global Markets to 2024, Strategies, Trends, Volume & Price Forecasts by Pathogen & Country

    author_avatar
    NASDAQ Market News

    Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program

    author_avatar
    NASDAQ Market News

    Vaxart Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    author_avatar
    NASDAQ Market News